1460882800-4d3a6439-bee2-4cc2-98cf-99aa359a4f3a

1. A fence for tennis practice comprising a plurality of flat rigid mesh panels (18) secured together side by side to form a substantially flat continuous surface, each adjacent pair of panels being connected to and supported by an upright rigid post (10) having a flat front surface abutting a rear surface of one of said pair of panels, an edge (26) of said abutting panel being bent around said post to abut a side surface of the post and the other panel of the pair having an edge (28) bent back to abut the bent-back edge of the other panel, the said bent-back edges being secured together and to the side surface of the post.
2. A tennis practice fence according to claim 1 wherein a noise reduction strip (30) is interleaved between said front surface of the post (10) and the abutting rear surface of the panel (18).
3. A tennis practice fence according to claim 2 wherein the noise reduction strip (30) is made of a hard rubber or plastics material.
4. A tennis practice fence according to any preceding claim which comprises at least four said mesh panels (18) supported by at least five said posts (10).
5. A tennis practice fence according to any preceding claim wherein the posts supporting the rigid mesh panels include a central post dividing the fence into two equal halves.
6. A tennis practice fence according to any preceding claim wherein the tops of adjacent posts are connected together by horizontal cross members (14).
7. A tennis practice fence according to any preceding claim further comprise a transverse member or members (16) extending between the posts (10), shaped and positioned to represent the top of a tennis net.
8. A tennis practice fence according to any preceding claim wherein the mesh panels (18) comprise two arrays of parallel coplanar wires (36, 58), the two arrays being secured together with their wires extending in transverse directions in adjacent planes.
9. A tennis practice fence according to claim 8 wherein the wires (58) of one array are vertical and the wires (36) of the other are horizontal.
10. A tennis practice fence according to claim 8 or claim 9 wherein the wires (36) of one array are more closely spaced than those of the other and extend in a plane in front of the plane containing the less closely spaced wires (58), to form the rebound surface.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of treatment of mutant RAS cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein -J- is independently:
and wherein \u2014R is independently: \u2014H, -Me, \u2014F, \u2014Cl, \u2014Br, or \u2014I;
and wherein \u2014R is positioned meta- or para- on the phenyl ring.
2. A method according to claim 1, wherein the mutant RAS cancer is:
mutant RAS melanoma;
mutant RAS lung cancer;
mutant RAS colorectal cancer;
mutant RAS pancreatic cancer;
mutant RAS thyroid cancer;
mutant RAS seminoma;
mutant RAS myelodisplastic syndrome;
mutant RAS liver cancer;
mutant RAS leukemia;
mutant RAS sarcoma;
mutant RAS lymphoma;
mutant RAS gastrointestinal cancer;
mutant RAS bladder cancer;
mutant RAS kidney cancer;
mutant RAS ovarian cancer;
mutant RAS bile duct cancer;
mutant RAS cervix carcinoma;
mutant RAS glioma;
mutant RAS breast cancer;
mutant RAS endometrial cancer;
mutant RAS stomach cancer;
mutant RAS head and neck cancer;
mutant RAS oesophagus carcinoma; or
mutant RAS prostate cancer.
3. A method according to claim 1, wherein the mutant RAS cancer is:
mutant RAS melanoma;
mutant RAS lung cancer;
mutant RAS colorectal cancer;
mutant RAS pancreatic cancer;
mutant RAS thyroid cancer;
mutant RAS seminoma;
mutant RAS myelodisplastic syndrome;
mutant RAS liver cancer;
mutant RAS leukemia;
mutant RAS sarcoma;
mutant RAS lymphoma;
mutant RAS gastrointestinal cancer;
mutant RAS bladder cancer;
mutant RAS kidney cancer;
mutant RAS ovarian cancer;
mutant RAS bile duct cancer; or
mutant RAS cervix carcinoma.
4. A method according to claim 1, wherein the mutant RAS cancer is:
mutant RAS melanoma;
mutant RAS lung cancer;
mutant RAS colorectal cancer;
mutant RAS pancreatic cancer; or
mutant RAS thyroid cancer.
5. A method according to claim 4, wherein the compound is selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein \u2014RA is independently \u2014H, -Me, \u2014F, \u2014Cl, \u2014Br, or \u2014I; and
wherein \u2014RA is positioned meta- or para- on the phenyl ring.
6. A method according to claim 5, wherein \u2014RA is \u2014H.
7. A method according to claim 5, wherein \u2014RA is -Me.
8. A method according to claim 5, wherein \u2014RA is \u2014F.
9. A method according to claim 5, wherein \u2014RA is \u2014Cl.
10. A method according to claim 5, wherein the compound is selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein \u2014RA is independently \u2014H, -Me, \u2014F, \u2014Cl, \u2014Br, or \u2014I.
11. A method according to claim 10, wherein \u2014RA is independently \u2014H, -Me, \u2014F, or \u2014Cl.
12. A method according to claim 5, wherein the compound is selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:
wherein \u2014RA is independently \u2014H, -Me, \u2014F, \u2014Cl, \u2014Br, or \u2014I.
13. A method according to claim 12, wherein \u2014RA is independently \u2014H, -Me, \u2014F, or \u2014Cl.
14. A method according to claim 5, wherein the compound is selected from the following compound and pharmaceutically acceptable salts thereof:
15. A method according to claim 5, wherein the compound is selected from the following compound and pharmaceutically acceptable salts thereof:
16. A method according to claim 5, wherein the compound is selected from the following compound and pharmaceutically acceptable salts thereof:
17. A method according to claim 5, wherein the compound is selected from the following compound and pharmaceutically acceptable salts thereof:
18. A method according to claim 4, wherein the compound is selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein \u2014RB is independently \u2014H, -Me, \u2014F, \u2014Cl, \u2014Br, or \u2014I; and
wherein \u2014RB is positioned meta- or para- on the phenyl ring.
19. A method according to claim 18, wherein \u2014RB is independently \u2014H, -Me, \u2014F, or \u2014Cl.
20. A method according to claim 18, wherein \u2014RB is \u2014H.
21. A method according to claim 18, wherein \u2014RB is -Me.
22. A method according to claim 18, wherein \u2014RB is \u2014F.
23. A method according to claim 18, wherein \u2014RB is \u2014Cl.
24. A method according to claim 18, wherein the compound is selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein \u2014RB is independently \u2014H, -Me, \u2014F, \u2014Cl, \u2014Br, or \u2014I.
25. A method according to claim 24, wherein \u2014RB is independently \u2014H, -Me, \u2014F, or \u2014Cl.
26. A method according to claim 18, wherein the compound is selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein \u2014RB is independently \u2014H, -Me, \u2014F, \u2014Cl, \u2014Br, or \u2014I.
27. A method according to claim 26, wherein \u2014RB is independently \u2014H, -Me, \u2014F, or \u2014Cl.
28. A method according to claim 18, wherein the compound is selected from the following compound, and pharmaceutically acceptable salts thereof:
29. A method according to claim 18, wherein the compound is selected from the following compound, and pharmaceutically acceptable salts thereof:
30. A method according to claim 18, wherein the compound is selected from the following compound, and pharmaceutically acceptable salts thereof: